Song-Chang Lin1, Li-Yuan Yu-Lee2, Sue-Hwa Lin3,4. 1. Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA. slin4@mdanderson.org. 2. Department of Medicine, Baylor College of Medicine, Houston, TX, 77030, USA. 3. Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA. 4. Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Abstract
PURPOSE OF REVIEW: Prostate cancer bone metastasis is the lethal progression of the disease. The disease frequently presents with osteoblastic lesions in bone. The tumor-induced bone can cause complications that significantly hamper the quality of life of patients. A better understanding of how prostate cancer induces aberrant bone formation and how the aberrant bone affects the progression and treatment of the disease may improve the therapies for this disease. RECENT FINDINGS: Prostate cancer-induced bone was shown to enhance tumor growth and confer therapeutic resistance in bone metastasis. Clinically, Radium-223, an alpha emitter that selectively targets bone, was shown to improve overall survival in patients, supporting a role of tumor-induced bone in prostate cancer progression in bone. Recently, it was discovered that PCa-induced aberrant bone formation is due, in part, from tumor-associated endothelial cells that were converted into osteoblasts through endothelial-to-osteoblast (EC-to-OSB) conversion by tumor-secreted BMP4. The unique bone-forming phenotype of prostate cancer bone metastasis plays a role in prostate cancer progression in bone and therapy resistance. Therapies that incorporate targeting the tumor-induced osteoblasts or EC-to-OSB conversion mechanism may reduce tumor-induced bone formation and improve therapy outcomes.
PURPOSE OF REVIEW: Prostate cancer bone metastasis is the lethal progression of the disease. The disease frequently presents with osteoblastic lesions in bone. The tumor-induced bone can cause complications that significantly hamper the quality of life of patients. A better understanding of how prostate cancer induces aberrant bone formation and how the aberrant bone affects the progression and treatment of the disease may improve the therapies for this disease. RECENT FINDINGS:Prostate cancer-induced bone was shown to enhance tumor growth and confer therapeutic resistance in bone metastasis. Clinically, Radium-223, an alpha emitter that selectively targets bone, was shown to improve overall survival in patients, supporting a role of tumor-induced bone in prostate cancer progression in bone. Recently, it was discovered that PCa-induced aberrant bone formation is due, in part, from tumor-associated endothelial cells that were converted into osteoblasts through endothelial-to-osteoblast (EC-to-OSB) conversion by tumor-secreted BMP4. The unique bone-forming phenotype of prostate cancer bone metastasis plays a role in prostate cancer progression in bone and therapy resistance. Therapies that incorporate targeting the tumor-induced osteoblasts or EC-to-OSB conversion mechanism may reduce tumor-induced bone formation and improve therapy outcomes.
Entities:
Keywords:
Bone metastasis; EC-to-OSB conversion; Osteocrines; Prostate cancer; Tumor-induced bone
Authors: Yu-Chen Lee; Chien-Jui Cheng; Mehmet A Bilen; Jing-Fang Lu; Robert L Satcher; Li-Yuan Yu-Lee; Gary E Gallick; Sankar N Maity; Sue-Hwa Lin Journal: Cancer Res Date: 2011-06-13 Impact factor: 12.701
Authors: Matthew Smith; Johann De Bono; Cora Sternberg; Sylvestre Le Moulec; Stéphane Oudard; Ugo De Giorgi; Michael Krainer; Andries Bergman; Wolfgang Hoelzer; Ronald De Wit; Martin Bögemann; Fred Saad; Giorgio Cruciani; Antoine Thiery-Vuillemin; Susan Feyerabend; Kurt Miller; Nadine Houédé; Syed Hussain; Elaine Lam; Jonathan Polikoff; Arnulf Stenzl; Paul Mainwaring; David Ramies; Colin Hessel; Aaron Weitzman; Karim Fizazi Journal: J Clin Oncol Date: 2016-07-11 Impact factor: 44.544
Authors: Yu-Chen Lee; Martina Srajer Gajdosik; Djuro Josic; James G Clifton; Christopher Logothetis; Li-Yuan Yu-Lee; Gary E Gallick; Sankar N Maity; Sue-Hwa Lin Journal: Mol Cell Proteomics Date: 2014-12-19 Impact factor: 5.911
Authors: Yu-Chen Lee; Jung-Kang Jin; Chien-Jui Cheng; Chih-Fen Huang; Jian H Song; Miao Huang; Wells S Brown; Sui Zhang; Li-Yuan Yu-Lee; Edward T Yeh; Bradley W McIntyre; Christopher J Logothetis; Gary E Gallick; Sue-Hwa Lin Journal: Mol Cancer Res Date: 2013-01-21 Impact factor: 5.852
Authors: Zhi Gang Li; Paul Mathew; Jun Yang; Michael W Starbuck; Amado J Zurita; Jie Liu; Charles Sikes; Asha S Multani; Eleni Efstathiou; Adriana Lopez; Jing Wang; Tina V Fanning; Victor G Prieto; Vikas Kundra; Elba S Vazquez; Patricia Troncoso; Austin K Raymond; Christopher J Logothetis; Sue-Hwa Lin; Sankar Maity; Nora M Navone Journal: J Clin Invest Date: 2008-08 Impact factor: 14.808
Authors: Michael J Morris; Neeta Pandit-Taskar; Jorge Carrasquillo; Chaitanya R Divgi; Susan Slovin; William K Kelly; Dana Rathkopf; Gretchen A Gignac; David Solit; Lawrence Schwartz; Ryan D Stephenson; Christina Hong; Anthony Delacruz; Tracy Curley; Glenn Heller; Xiaoyu Jia; Joseph O'Donoghue; Steven Larson; Howard I Scher Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: Arti Verma; Sandeep Artham; Abdulrahman Alwhaibi; Mir S Adil; Brian S Cummings; Payaningal R Somanath Journal: Biochem Pharmacol Date: 2020-03-30 Impact factor: 5.858
Authors: Nathalie Bock; Thomas Kryza; Ali Shokoohmand; Joan Röhl; Akhilandeshwari Ravichandran; Marie-Luise Wille; Colleen C Nelson; Dietmar W Hutmacher; Judith A Clements Journal: Sci Adv Date: 2021-06-30 Impact factor: 14.136
Authors: Astrid Børretzen; Karsten Gravdal; Svein A Haukaas; Christian Beisland; Lars A Akslen; Ole J Halvorsen Journal: J Pathol Clin Res Date: 2019-10-01